111, Inc. (YI) AI Stock Analysis

111, Inc., headquartered in Shanghai, China, operates an integrated healthcare platform serving both B2B and B2C markets across online and offline channels. The company distributes prescription and over-the-counter pharmaceuticals, traditional Chinese medicines, nutritional supplements, medical devices, personal care items, and baby products. It provides online consultation and electronic prescription services, alongside an online marketplace where third-party sellers connect with pharmacies. 111, Inc. also provides supply chain and operational solutions, including warehousing, logistics, procurement, software development, data integration services, and online loan applications for affiliated pharmacies and wholesalers.

Annual revenue rose from $12.43B in FY2021 to a peak of $14.95B in FY2023 before contracting to $14.40B in FY2024 and $12.21B in FY2025, representing a 15.2% decline in FY2025. Gross margin expanded from 5.0% in FY2021 to 5.8% in FY2025. Operating margins improved from -5.2% in FY2021 to -0.1% in FY2025, while net losses narrowed significantly from -$669.8M in FY2021 to -$16.8M in FY2025. For the trailing twelve months, revenue stood at $10.48B with an operating margin of -1.0% and a net profit margin of -1.0%. In the latest quarter ended June 30, 2026, quarterly revenue fell 28.3% year-over-year.

As of June 30, 2026, 111, Inc. held $381.3M in cash and short-term investments against total debt of $282.0M, resulting in a net cash position of $99.3M. Total assets stood at $1.79B with a current ratio of 1.07, while shareholders' equity was -$114.4M. Operating cash flow improved to $119.1M in FY2025, down from $263.0M in FY2024, yielding free cash flow of $114.7M after capital expenditures of $4.5M. The company's share count increased 6.1% over five years.

111, Inc. closed at $3.13 on October 16, 2026, giving it a market capitalization of $27.5M and an enterprise value of $31.2M. The stock trades at a trailing price-to-earnings ratio of 0.3x, compared to 24.6x for the median of its US-listed Healthcare peers. Its price-to-sales multiple is 0.0x versus the peer median of 4.1x, and its enterprise value-to-EBITDA is 0.1x compared to the peer median of 12.0x. The stock has dropped 28.9% over the past year and 94.5% over five years, compared to gains of 16.8% and 83.0%, respectively, for the S&P 500.

Analysts have established a mean price target of $5.96 for 111, Inc., which sits 90.4% above its last close of $3.13. Consensus estimates project next fiscal year revenue of $16.75B, representing an estimated growth rate of 9.9%, alongside an EPS estimate of $0.00. Over the last four quarters, the company delivered two EPS beats.

This page is an AI-written research summary of 111, Inc. (YI). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: YI income statement, YI balance sheet, YI key metrics, YI analyst forecast, YI chart. See the YI stock overview for the latest quote and news.